6 days ago · In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.The patients had a form of kidney cancer called clear cell renal cell carcinoma and were deemed at high risk for recurrence due to the advanced stage of the ...

Feb 5, 2025 · But kidney cancer is a disease with fewer mutations, and therefore fewer targets to manufacture the vaccine. It was important for the investigators to learn as much as possible from this early phase study about how the vaccine influences an immune response to the tumor.

11 hours ago · A personalized cancer vaccine has been shown to help prevent future relapse among patients with clear cell renal cell carcinoma, a type of kidney cancer, according to data from a phase 1 clinical trial published in Nature.. Among the nine patients with stage 3 and 4 clear cell renal cell carcinoma who were enrolled onto the trial, a successful anti-cancer immune response was observed with the ...

5 days ago · A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to long-lasting T cell expansion and no disease recurrence after 40 months.

Feb 5, 2025 · All nine patients with advanced kidney cancer in an early-phase trial of a personalized therapeutic vaccine had successful anti-cancer immune responses and remained cancer-free approximately three years after treatment. A therapeutic vaccine is used after disease sets in, aiming to induce immunity to alter the course of disease. Each patient’s vaccine was created with information found by ...

6 days ago · A personalized cancer vaccine (PCV) to target neoantigens (mutant proteins expressed only by cancer cells) was delivered to individuals with stage III–IV kidney cancer (renal cell carcinoma; RCC ...

Jan 7, 2019 · Scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery.

Researchers want to see how well a personalized vaccine works for people with kidney cancer when given with pembrolizumab immunotherapy. The people in this study have renal cell carcinoma that was or will be removed with surgery.

5 days ago · The vaccines are personalised via neoantigens extracted from the patient’s tumour tissue during tumour removal surgery. Credit: Shutterstock / Pormezz. All nine patients in a Phase I investigator-led trial of a personalised kidney cancer vaccine have successfully generated anti-cancer immune ...

5 days ago · THURSDAY, Feb. 6, 2025 (HealthDay News) -- A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their tumors, explained a team led by Dr ...